BiotechTube
Tourmaline Bio

Tourmaline Bio

New York, United States· Est.
tourmalinebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

Tourmaline Bio is a late-stage, clinical-stage biotech focused on targeting the IL-6 pathway to treat inflammatory and immune diseases. The company appears to be advancing at least one product candidate through clinical development, leveraging a team of experienced entrepreneurs, physicians, and industry experts. As a private, pre-revenue company founded in 2021, it is positioned in a competitive but high-potential therapeutic area with significant unmet needs.

Inflammatory DiseasesImmune Diseases

Technology Platform

IL-6 (Interleukin-6) pathway inhibition using antibody/biologic therapeutics.

Funding History

1
Total raised:$80M
Series A$80M

Opportunities

The IL-6 pathway is validated with expanding potential in new inflammatory and immune indications beyond rheumatology, such as cardiovascular disease.
Successfully developing a therapy for a high-unmet-need area could capture a significant market and establish a new standard of care.

Risk Factors

High clinical development risk, including potential trial failure.
Faces competition from established IL-6 inhibitors.
As a private, pre-revenue company, it carries significant financing and execution risk, with dependence on a focused pipeline.

Competitive Landscape

The IL-6 inhibitor market is competitive with approved therapies from major pharma (e.g., Roche's Actemra, Sanofi's Kevzara). Tourmaline must differentiate through superior efficacy, safety, dosing, or by targeting novel, underserved indications to succeed.

More companies in Biologics / Biosimilars →More companies in United States →